AI assistant
CYTOKINETICS INC — Director's Dealing 2021
Mar 4, 2021
30870_dirs_2021-03-04_97f49dc2-c23d-488d-a52d-faf3f080eb0a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CYTOKINETICS INC (CYTK)
CIK: 0001061983
Period of Report: 2021-03-02
Reporting Person: Cragg David (SVP Human Resources)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-02 | Common Stock | A | 25000 | $0.0 | Acquired | 164775 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-02 | Incentive Stock Option (right to buy) | $19.42 | A | 10121 | Acquired | 2031-03-01 | Common Stock (10121) | Direct |
| 2021-03-02 | Non-Qualified Stock Option (right to buy) | $19.42 | A | 34879 | Acquired | 2031-03-01 | Common Stock (34879) | Direct |
Footnotes
F1: Comprised of restricted stock units that will vest over 3 years, with 40% vesting on the 1-year anniversary of the grant, an additional 40% vesting on the 2-year anniversary of the grant, and the final 20% vesting on the 3-year anniversary of the grant.
F2: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.
F3: This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.